Neovacs Gross Margin

What does Neovacs do? Neovacs SA develops Kinoids, drug-candidates targeting autoimmune, inflammatory, and cancerous diseases through active immunotherapy. The company focuses on TNF-Kinoids, IFN-Kinoids, and VEGF-Kinoids for conditions like Crohn’s disease, Rheumatoid Arthritis, and lupus. Neovacs SA operates in France and the United States, with a 70% ownership stake in Neostell, a joint venture established with Stellar Biotechnologies Inc in May 2016. The firm’s revenue comes from research and development contracts, licensing agreements for its Kinoid therapies, and potential future sales of approved treatments. Neovacs SA targets pharmaceutical companies and research institutions seeking innovative immunotherapy solutions. Its primary customers include biotechnology firms interested in developing new treatments for autoimmune and inflammatory diseases. The company’s portfolio of Kinoids, including TNF-Kinoids for Crohn’s disease and Rheumatoid Arthritis, appeals to partners looking to expand their therapeutic offerings. Neostell, the 70% owned joint venture, further supports the company’s strategy by enhancing its research and development capabilities. The company’s business model relies on the development of Kinoids as drug-candidates, which are designed to induce antibody responses in patients. By focusing on specific disease targets like TNF, IFN, and VEGF pathways, Neovacs SA positions itself as a specialized provider in immunotherapy. Its operations span France and the United States, with a dedicated team of 24 full-time employees driving research efforts. The joint venture with Stellar Biotechnologies Inc strengthens its market presence and expands its pipeline of potential treatments. Neovacs is one of the most popular companies on Eulerpool.